TLDR
- Analyst Erin Wright from Morgan Stanley maintains Buy rating on UNH with price target of $375
- Wright designates UNH as her Top Pick following positive momentum in managed care sector
- Medicare Advantage final rate notice provides enhanced clarity on 2026 reimbursement structure
- Q1 earnings announcement scheduled for April 21; analysts project EPS of $6.60 compared to $7.20 prior year
- Bernstein SocGen maintains Outperform stance with $411 price objective for UNH
Morgan Stanley approaches UNH’s Q1 earnings release with strong confidence. Analyst Erin Wright maintained her Buy rating alongside a $375 price objective, designating UnitedHealth as her premier selection within managed care coverage.
UnitedHealth Group Incorporated, UNH
This endorsement follows a challenging period for the equity. Medicare Advantage concerns and medical cost uncertainties have created pressure on UNH shares. Wright anticipates these challenges are beginning to diminish.
The final Medicare Advantage rate notice stands as a primary driver behind her strengthened outlook. The notice delivered improved transparency regarding 2026 reimbursement structures and supported projections that UNH can continue enhancing MA margin performance.
Wright maintains close attention on the Optum Health transformation. Following challenging times within that division, she observes increasing evidence that the segment is progressing favorably.
She highlighted AI-powered operational improvements as a developing positive factor. While still in early stages, Wright believes UnitedHealth’s technology commitments could enhance operations substantially across extended timeframes.
Q1 Earnings on April 21
UNH releases first-quarter financial results on Tuesday, April 21. Wright anticipates a quarter broadly aligned with expectations, without significant deviations.
Wall Street consensus projects Q1 revenue reaching $109.52 billion, showing slight decline from $109.58 billion during the comparable period last year. EPS projections stand at $6.60, versus $7.20 from the previous year.
Market participants will monitor Medicare Advantage margin trajectories, medical cost developments, and management commentary regarding Optum Health’s turnaround progress. AI efficiency advancements and full-year guidance will draw considerable attention.
UNH presently trades at $316.40. Based on this price level, Morgan Stanley’s $375 objective represents approximately 18.5% potential appreciation.
Bernstein Adds Its Voice
Bernstein SocGen demonstrates even stronger conviction. Analyst Lance Wilkes maintained an Outperform rating alongside a $411 price objective, characterizing UNH’s valuation as compelling.
The firm anticipates broader sector improvement as Medicare Advantage margins advance from their low point following the MA rate adjustment and competitive exits.
Bernstein identifies company-specific margin enhancement opportunities as UNH discontinues unprofitable MA and Optum Health offerings. The firm forecasts robust EPS expansion across the upcoming four-year period.
The stock carries a P/E multiple of 24. For reference, the aggregated Wall Street price objective across 18 Buy ratings and 5 Hold ratings reaches $366.24 — representing approximately 15.75% upside potential from present levels.
One consideration deserving attention: Leerink identified that UNH maintains exposure to expanded RADV audits conducted by CMS. Sixty contracts encompassing 92% of its Medicare Advantage enrollment face review — a substantial increase from zero in 2018. These audits commenced processing during April 2025.
UBS recently incorporated UNH into its Global High-Quality Dividend Stock List, recognizing the company as a dependable dividend provider.
